Aurinia Pharmaceuticals AUPH Business Segments
| Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | ||
|---|---|---|---|---|---|---|
| Concentration risk percentage by Product | ||||||
| Collaboration partnership | 1.8%-1.0pp | 1.8%-1.0pp | 1.8%-1.0pp | 1.8%-1.0pp | 2.8%+0.2pp | |
| Specialty pharmacy A | 12.3%0.0pp | 12.3%0.0pp | 12.3%0.0pp | 12.3%0.0pp | 12.3%-0.5pp | |
| Specialty pharmacy B | 9.5%-0.3pp | 9.5%-0.3pp | 9.5%-0.3pp | 9.5%-0.3pp | 9.8%-0.3pp | |
| Revenue by Geography | ||||||
| Japan | $4.8M-23.3% | $4.8M-23.3% | $4.8M-23.3% | $4.8M-23.3% | $6.26M+42.6% | |
| U.S. | $65.96M+25.6% | $65.96M+25.6% | $65.96M+25.6% | $65.96M+25.6% | $52.52M+33.0% | |
| Total property, equipment and right-of-use lease assets by Geography | ||||||
| Canada | $336K-22.4% | —— | —— | —— | $433K-18.0% | |
| France | $0-100% | —— | —— | —— | $782K— | |
| Switzerland | $73.87M-19.1% | —— | —— | —— | $91.29M-16.0% | |
| U.S. | $5.37M-15.6% | —— | —— | —— | $6.37M-13.1% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Aurinia Pharmaceuticals break its business down?
- Aurinia Pharmaceuticals (AUPH) reports concentration risk percentage by product across 3 parts — Collaboration partnership, Specialty pharmacy A and Specialty pharmacy B. Each is extracted from the segment footnotes and tracked over time.
- Where does Aurinia Pharmaceuticals's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Aurinia Pharmaceuticals's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.